Assessing clonal diversity in acute myeloid leukemia by Christensen, Weston Daniel
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2016
Assessing clonal diversity in acute
myeloid leukemia
https://hdl.handle.net/2144/16766
Boston University
   
BOSTON UNIVERSITY  
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
ASSESSING CLONAL DIVERSITY IN 
ACUTE MYELOID LEUKEMIA 
 
 
 
 
By 
 
 
 
 
WESTON CHRISTENSEN 
 
B.S., Western Washington University, 2014 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2016  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2016 by 
 WESTON CHRISTENSEN 
 All rights reserved  
   
Approved by 
 
 
 
 
First Reader   
 Vickery Trinkaus-Randall, Ph.D. 
 Professor of Biochemistry and Ophthalmology 
 
 
 
Second Reader   
 Jerry Radich, M.D. 
 Member, Clinical Research Division, Fred Hutchinson Cancer Research    
      Center  
 Professor, University of Washington School of Medicine 
 Director, Molecular Oncology Lab 
 
  iv 
ACKNOWLEDGMENTS 
 
Thanks primarily to Drs. Jerry Radich and Amy Paguirigan for mentoring me 
through the development of this thesis; the opportunity to work with them has been a 
fantastic one and I was lucky to get it. Additional thanks go to Jordan Smith for laying 
the ground work, Zaneta Holman for keeping me on track and the lab organized, and to 
everyone at the Radich lab for showing me around and accommodating me so warmly 
while I was typing away in the corner. All of the people at the Fred Hutchinson Cancer 
Research Center were incredibly welcoming and a privilege to work with. Great things 
are happening there. 
  
  v 
ASSESSING CLONAL DIVERSITY IN ACUTE MYELOID LEUKEMIA 
WESTON CHRISTENSEN 
ABSTRACT 
Clonal diversity in cancer has been proposed as a mechanism underlying patient-
to-patient variability in therapeutic response, as well as the variability in the likelihood of 
relapse and the time to relapse of acute myeloid leukemia (AML) as well as other 
cancers. As a neoplasm develops it often continues to mutate, diversifying into differing 
clonal populations. Darwinian evolutionary pressures such as inherent fitness imbalances, 
immune system interactions, and chemotherapy treatments target sensitive clones and 
drive competition between the clonal populations; selecting for dynamic and resistant cell 
lines. In this way clonal diversity is conceivable as an impediment to a complete 
remission with more populations offering more opportunities for therapy resistance. Bulk 
next generation sequencing (NGS) is currently used to assess clonal composition in 
leukemia but requires several broad assumptions be made, which can result in incorrect 
assessments of diversity. Factors such as differences in zygosity of mutations, convergent 
evolution, or contamination with wild-type/non-cancerous cells can artificially raise or 
lower reported variable allele frequencies (VAF), leading to errors in clonal assessments. 
To examine discrepancies between the actual clonal structure and the clonal structures 
determined through bulk sequencing we developed a novel method of sampling the cell 
population to identify concurrent mutations. We first created an in silico model which 
randomly draws cell samples from a simulated tumor multiple times and calculates the 
VAF for each mutant allele in each sample. By tracking the correlation of mutations 
  vi 
between sample replicates, a clonal composition that is not observable from the bulk 
NGS VAF becomes apparent. We then created in vitro model tumors from AML cell 
lines, isolated low cell number samples via flow cytometry, and applied a 
multiplex/nested PCR protocol with pyrosequencing to quantify VAFs in each sample. 
Again, by calculating the correlation of mutant alleles between replicates, previously 
unseen with NGS characteristics of the clonal structure becomes evident. Population 
sampling analysis may potentially offer a solution for clarifying how we can interpret 
NGS clonal analyses.   
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INTRODUCTION 
Acute Myeloid Leukemia 
One of the most feared outcomes of any cancer treatment is relapse with a more 
aggressive and unmanageable cancer emerging from the post-treatment remission of the 
original. About one in five of all cancer survivors will experience a relapse within five 
years (Baker, Denniston, Smith, & West, 2005). Patients with acute myeloid leukemia 
(AML) face an even worse prognosis with much higher relapse and mortality rates (Szer, 
2012).  
In the United States the incidence of AML is 3.6 people per 100,000 per year, 
with over 11,000 new cases every year (Szer, 2012). While 20% of these cases are 
intractable to initial chemotherapy, the remainder will respond favorably and enter 
remission. Unfortunately most patients in remission will relapse, with an estimated 
incidence of relapse for patients that achieved a complete remission between 67% and 
92% (Byrd et al., 2002). The basis of this relapse has been proposed to be related to 
clonal evolution, i.e. the continuous development of diseased cells with novel mutations 
generating new daughter colonies, increasing the range of targets that a regimen of 
chemotherapy must hit (Ding et al., 2012). Due to the role of clonal diversity in relapse 
assessment the clonal populations present in AML, and the relationship between clones 
present in neoplasms pre-treatment and post-treatment has become of interest to the 
scientific community. The high relapse rate of AML specifically makes it an excellent 
model for investigating clonality. Furthermore, successes in identifying impediments to 
full remissions would not only aide treatment of leukemia, but many cancers.  
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Clonality of Cancer 
As modern cancer research has been evolving since its inception in the mid-1900s 
the direction of treatment has been shifting away from “cure-alls” and “wonder-drugs” to 
more precise and personalized therapies. This is due to both the understanding of the 
large variability that may be present in the genotypes of phenotypically identical cancers 
and the investigation into the potential clonal heterogeneity of individual cancers 
(Fernald, Capriotti, Daneshjou, Karczewski, & Altman, 2011; Paguirigan et al., 2015; 
Slamon et al., 2001). Previous models of clonality predicted a linear cancer model, 
beginning with an initial series of mutations that incrementally increase the fitness of a 
single clone which then expands to occupy the entire homogenous cancer population 
(Fearon, Hamilton, & Vogelstein, 1987). This has been shown to not be the whole 
situation. With the recent methodological advances in gene mutation detection, we can 
detect a surprising degree of heterogeneity between and within tumors (Navin et al., 
2011). Distinct clonal differences can be observed inter-tumoral between primary tumors 
and subset metastasis in metastatic medulloblastoma as well as intra-tumoral in 
pancreatic and renal carcinomas (Gerlinger et al., 2012; Wu et al., 2012; Yachida et al., 
2010). A complex network of evolutionary pressures creates genotypic “trees” for 
neoplasms with clonal populations experiencing competition within a tumor.  
External and internal pressures from chemotherapy treatments, cell resilience, 
resource availability, and growth potential all play a role in the neoplasm’s development, 
driving the success or failure of differing cell populations, or clonal populations, within a 
seemingly contiguous malignancy (Figure 1)(Greaves & Maley, 2012). In previous 
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cancer models relapse was explained by a failure of the intensity of the treatment to 
impact all effectively identical clones, driving physicians to extended and more rigorous 
treatment regimens. The new clonal model suggests that relapse is instead partially due to 
the medicinally based selection for therapy-resistant sub-clones (Turner & Reis-Filho, 
2012). This has a particular relevance to leukemia; 30% of AML patients at initial 
diagnosis will contain some detectable allele load of the prognostically unfavorable FMS-
like tyrosine kinase 3 (FLT3) mutations, such as internal tandem duplications (FLT3-
ITD) or the rarer substitution mutations such as D835. Both of these mutations impart 
resistance to the typical first-round AML treatment, of tyrosine kinase inhibitors (TKIs) 
(Levis, 2013). Patients with FLT3 mutations who are treated with TKIs share similar 
remission rates of other AML subtypes; however, relapse is far more common and often -
-although not always-- associated with a higher FLT3-ITD associated mutation allele 
burden (Jan & Majeti, 2013). This pattern suggests that in these patients prior to 
treatment there existed a relatively small clonal population that contained a mutation on 
the FLT3 allele and was selected for by therapeutics which eradicated its competing 
colonies. With no other competition and a resistance to the therapeutics the clone could 
proliferate, thus increasing the number of cells that contain a mutation --and the FLT3-
ITD variant allele frequency (VAF) -- until the patient was in full relapse with a now 
therapeutically resistant cancer. In this way, an increase in a neoplasms genetic clonal 
diversity can play a role in the deterioration of a patient’s prognosis. Increasing clonal 
diversity has been revealed to predict malignancy in Barrett’s esophagus and AML (Ding 
et al., 2012; Maley et al., 2006). By learning more about the impact of clonal diversity 
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and the relevance of specific recurrent mutations, physicians gain a powerful tool in 
designing treatments; primarily targeting aggressive cell populations, predicting 
imminent evolutions, and planning therapeutic regimens around probable remissions. 
 
Figure 1. Clonal evolution and diversity.  Initial regimens of chemotherapy, while 
often effective, may not eradicate every possible evolutionary product of a neoplasm. 
One or more surviving clones can grow to establish novel colonies and bring about a 
relapse. Enduring colonies also have the potential to further diversify with all subsequent 
colonies now at least partially resistant to therapy.  
 
 
With an almost limitless permutation of potential clones that are possible and 
identifiable it becomes necessary to classify them by their unique mutations that lead to 
recognizable features, both phenotypic and genotypic. These mutations are often labeled 
either as founder, driver, or passenger mutations. Founder mutations are the least 
common and are responsible, in part, for the founding of a neoplasm colony. Generally at 
least two founder mutations are needed for tumor’s development from benign to 
malignant; one in a tumor suppressor gene which permits the cell to embark in rampant 
growth/expansion without self-destruction and one in a growth regulation gene which 
provides the stimulus for the proliferation of the cell (Harada & Harada, 2015). Driver 
mutations are the activating oncogenic changes that push a colony already containing a 
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founding clone toward ever more aggressive and resilient expansions. Passenger 
mutations are relatively common background mutations and not constrained to cancerous 
cells; most long-lived cells, specifically hematopoietic stem/progenitor cells (HSPC), will 
collect passenger mutations throughout their life with little to no detriment, although 
combinations can create effects similar to driver mutations (Corces-Zimmerman & 
Majeti, 2014). When appropriate founder and driver mutations occur in a cell that 
suitably increases its fitness, the colony expands and any passenger mutations present are 
“captured” to be carried forward with the expanding clone (Figure 2). Subsequent driver 
mutations that further increase the competitiveness of the host cell will “capture” the new 
passenger mutations resulting in new and categorically distinct clonal populations (Welch 
et al., 2012). Developing and diverging colonies with differing mutations can create a 
challenging scenario for treatment in which a single clonal subpopulation with a 
therapeutic-resistance granting mutation survives treatment and leads to relapse.  
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Figure 2. Driver and passenger mutations in clonal diversity. A) Healthy progenitor 
cells collect benign background mutations throughout their life (P0). B) An initiating 
driver mutation (Da) and C) clonal expansion “captures” the preexisting mutations and 
increases their frequency due to the colony’s increased fitness with different passenger 
mutations continuing to accrue (x and y). D) Subsequent new driving mutations (b and c) 
“capture” new passenger mutations and clonal expansion occurs. 
 
Sampling the Bulk Sample and Next Generation Sequencing 
The current approach to genomic based cancer treatment has been the sequencing 
of the cancer genome to detect which mutations are present. This is an expensive and 
underpowered process. However, the difficulty and expense of next generation 
sequencing (NGS) has steadily been on the decline, prompting the emergence of new 
diagnostic genomic tests. Standard NGS testing methods often involve “bulk” input, 
where large amounts of neoplasm sample are processed as one homogenous set. 
Unfortunately this method requires the introduction of the following assumptions into the 
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model: 1) All mutations that occur are heterozygous and the VAF of a mutation is one 
half of the cellular clonal population. 2) All mutations that occur are singular.  In other 
words, mutations in a given gene never arise separately in different clonal populations 
and mutations with higher allele frequencies come from “older” clones that are higher on 
the evolutionary tree and thus contain the same specific mutations. 3) Mutations with 
similar VAF are from the same clonal population of cells (e.g. if FLT3-D835 and NRAS-
Q61 both have a frequency of 25% then they are present only in the same clones). 4) All 
cells of the sample are malignant and no healthy cells were processed. This last 
supposition can artificially lower mutant allele VAF via allele dilution. Such assumptions 
vastly simplify the process of modeling a tumor’s development. By acknowledging that 
mutations can be either homozygous or wild-type, not only heterozygous, the range of 
possible clonal distributions significantly increases. Taken together these assumptions 
commonly lead to an underestimation of clonal complexity (Paguirigan et al., 2015) 
(Figure 3).  
To completely avoid the myriad problems put forth by bulk sequencing and obtain 
a total view of the clonal diversity present in a patient case it would be necessary to take 
nigh-infinite single-cell samples, sequence them individually, and plot VAFs for every 
gene. Such a project would take such an excess of time and resources as to render it 
infeasible.  
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Figure 3. Allele frequency determinations through bulk sequencing coupled with 
bulk sequencing assumptions can obscure underlying clonal diversity. A) Allele 
frequencies (AF) determined through bulk sequencing for genes X and Y. The clonal 
population is assumed to be twice the mutant AF, providing that the mutation is 
heterozygous. B) For any given AF multiple clonal populations are possible when solely 
considering the potential effects of zygosity on a sample. If the standard assumption that 
all mutations are heterozygous unless the AF exceeds 50% then population 1 would be 
assumed, however an infinite potential of population distributions are possible if 
homozygous mutations are considered. C) For any sample with non-zero AF for 
mutations in X and Y any individual cell may have one of nine mutational states, any or 
all of which may be a unique clonal populations. These figures are all representative of a 
simple 2 mutation system; increases in the number of mutations or the presence of 
replicated genes can complicate the model significantly.  
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Sampling the Clonal Structure 
To address bulk and single cell assay limitations, we devised an in vitro method 
which quantitates the allele frequencies of some of AML’s “high-profile” gene targets 
from low cell count, or low-cellular-throughput, samples. By tracking relative allele 
frequencies between multiple samples and comparing the correlation between mutant 
alleles one can hypothetically get an accurate representation of the clonal population. To 
prove the efficacy of this clonality assay’s multi-sample/low-throughput approach we 
show that 1) it is feasible and 2) more representative of the real clonal populations than 
bulk sequencing. Simulating a bulk sample we mixed several established AML cell lines 
at known ratios and, using a multiplex polymerase chain reaction (PCR) design coupled 
with pyrosequencing, determined the VAF of specific targets in replicated low-input 
samples. Through tracking the VAF of the targets through the multiple samples it is 
possible to determine which mutations are linked together and assess, in part, the clonal 
populations (Figure 4). 
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Figure 4. Determination of VAF in multiple low-throughput replicated samples can 
allow the determination of composition in a hypothetical cellular population. A) 
Multiple samples with approximately the same cell number are drawn from the bulk. B) 
Each sample will have slightly different proportions of cell lines, or clonal populations. 
C) Differing target allele frequencies of each cell line result in differing variable allele 
frequencies for each sample. D) Plotting variable allele frequencies for every replication 
against each other yields a correlation between each gene. E) The true allele frequencies 
of the hypothetical cell lines for comparison against the analytically derived clonality 
structure. F) Analysis of correlations reveals 3 different clonal populations, matching the 
hypothetical bulk. Increasing replications increases the accuracy of clonal population 
determination by adding more data points while increasing the number of cellular 
populations will decrease it. 
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Computer Modeling 
As a proof-of-concept and a potential future tool we developed an in silico 
computer model which simulates a multi-sample/low-throughput cell draw from a bulk 
sample. The program, named Cell Sampling, was used analyze the successfulness of the 
low-throughput clonality assay by comparing the VAF correlation results of the assay to 
the results seen in the program (Figure 5).  
Figure 5. Flow chart of experimental design and implementation.  Determination of 
allele frequencies in the individual cell lines provides a basis for creating heterogeneous 
tumor models with predictable VAFs. Computer modeling of the customized tumors 
allow for the optimization of the experimental parameters such as cell line proportions, 
sample size and replication number. After testing the computer model and the in vitro 
assay against the clonal populations and mutant allele frequencies known to be present 
the efficacy of both the assay and program in correctly predicting clonal populations and 
diversity can be evaluated. 
 
PCR Techniques 
Multiplex PCR is a useful method to create numerous amplicons simultaneously 
from one source, allowing the selection of several target genes to be amplified for a 
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relative VAF (Henegariu, Heerema, Dlouhy, Vance, & Vogt, 1997) (Figure 6). It ensures 
that all amplicons are coming from one homogenous source and the VAF will be 
consistent from sample to sample rather than several separate PCR reactions where the 
VAF is dependent on the potential random composition differences.  
 
Figure 6. Multiplex/nested/pyrosequencing protocol.  A) Whole cellular DNA with 
distinct six targets is placed into the multiplex to amplify all targets simultaneously. B) 
1st round product is separated into 6 different reactions with biotinylated primers for the 
nested product. C) Nested product with biotin beads are submitted for pyrosequencing. 
 
 
Nested PCR is a two-step process that can be used to amplify picogram amounts 
of DNA; the first-round amplifies multiple large outer targets which are then put into the 
second round reaction that individually amplifies smaller inner targets, the compounding 
amplification creates sufficient amounts of specific DNA product for genomic analysis. 
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Through the coupling of multiplex PCR with nested PCR we can separate several targets 
from low input concentrations of DNA and amplify the inner targets to sufficient levels 
for sequencing. The nested protocol also offers a source for error as well though; 
irregular interactions between multiplex amplicons can result in unbalanced target 
amplification and non-proportional VAF determination. 
Pyrosequencing 
Once the nested amplicon products of the target alleles have been produced with 
the hybrid multiplex/nested PCR, the sequence can be quantitatively analyzed with 
pyrosequencing (Md Fakruddin, 2012). Biotin labels on the inner amplification primers 
enable immobilization of the amplicons on sepharose beads that are subsequently 
incubated with sequencing primers and a preset sequential series of dNTPs. Nucleotides 
which are complementary to the template strand are incorporated to the sequencing strand 
in a 5’ to 3’ direction via Taq polymerase, releasing inorganic pyrophosphate (PPi) from 
dNTP. Enzymes present in solution (ATP sulfurylase, luciferase, and apyrase) along with 
substrates adenosine 5´ phosphosulfate (APS) and luciferin, generate visible light 
proportional to the amount of nucleotides incorporated. Any dNTPs not incorporated are 
rapidly degraded by apyrase (Figure 7). The proportional nature of the signal observed 
allows the calculation of VAF of specific mutations in the target sequence for each 
sample.  
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Figure 7. Pyrosequencing.  A) Nested PCR product binds immobilizing sepharose beads 
and sequencing strands bind to the product. B) Solution is sequentially incubated with a 
single dNTP types and Taq polymerase; Taq releases PPi with the addition of the 
nucleotide. C) ATP sulfurylase incorporates PPi into 5’ phosphosulfate to create ATP. D) 
ATP in vitro allows Luciferase to turn Luciferin into Oxyluciferin and light which is 
observed. E) dNTPs that do not match the template strand are not incorporated, degraded 
by an Apyrase enzyme, and no signal is observed. 
 
Targeted Alleles 
The AML cell lines KG1α, OCI-AML3, and MOLM14-L1 were used for this 
experiment. Circulating, non-adherent AML neoplasm cells provide an easy sampling 
model system for proof-of-concept research and the immortalized cell lines are generally 
robust. The selected targets for this clonality from these cell lines were the genes/codons 
DNMT3α-R882, EZH2-G628, FLT3-D835, FLT3-ITD, NRAS-Q61, STAG2-L526, and 
TET2-V218. The VAF for all targets with the exception of FLT3-ITD was determined 
through the multiplex/nested reaction coupled with pyrosequencing. FLT3-ITD was 
unique among these targets--it is a duplication mutation instead of a single nucleotide 
polymorphism.  Tandem duplications of a FLT3 codon increase the length of the 
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amplicon produced in the PCR. Quantitative determination of the ITD VAF was 
calculated by comparing the proportion of tandem duplication FLT3 to wild-type FLT3. 
Summary 
Bulk analysis is currently one of the most used methods of genetic analysis in 
AML treatment and oncology today. And while next generation sequencing of the bulk 
sampling may underestimate clonal complexity, strictly single cell analysis raises several 
concerns that must be addressed prior to widespread clinical use (such as time, resources 
and efficacy). We hypothesize that our strategy of low cell count input, DNA 
amplification, and analysis of the variable allele frequency will be capable of detecting 
clonal structure, which cannot be determined from bulk analysis of a simulated AML 
patient. If successful, this strategy would not only support caution in the evaluation bulk 
analysis results, but also potentially offer a third option of clonality analysis for future 
clinicians. 
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METHODS  
Cell Lines 
Three AML myeloblast cell lines were selected to simulate a bulk sample; KG1α, 
MOLM14-L1, and OCI-AML3. KG1α is a bone marrow myeloblast of a patient with 
AML, MOLM14 was derived from the peripheral blood of a patient who initially had 
myelodysplastic syndrome and the relapsed with full AML, and OCI-AML3 is a 
derivative from peripheral blood in an AML patient. The cells were separately cultured in 
Roswell Park Memorial Institute medium (RPMI) with 20% fetal bovine serum (FBS).  
Primer Design 
Sequences for the outer primers were found with the NCBI’s Primer-BLAST (Ye 
et al., 2012) and optimized for consistent and ideal annealing temperatures using 
OligoCalc (Kibbe, 2007). The resulting primers were run in NCBI’s nucleotide BLAST 
program to verify that the primers targeted the specified genes (Altschul, Gish, Miller, 
Myers, & Lipman, 1990). Finally all seven primer pairs were put through simultaneous in 
silico PCR with MFE-Primer 2.0 to ensure no cross amplification or dimer formation (Qu 
et al., 2012). The primers were was then ordered through Integrated DNA Technologies 
(IDT) (Appendix 1). Inner biotinylated primer and pyrosequencing primer designs were 
generated seperatelywith Pyromark by Qiagen and also ordered through IDT 
(Appendices 2 and 3).  
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Flow Cytometry 
Cell lines were previously analyzed using multiparameter flow cytometry to 
identify distinguishing cell surface markers.  We identified that KG1α is CD34+/CD14-, 
MOLM14-L1 is CD34-/CD14- and OCI-AML3 is CD34-/CD14+.  Cell lines were 
counted with a hemacytometer and pooled at an estimated fraction of 1/3 of each cell line 
with a total population of 3 million cells.  The mixture was spun down at 200rcf for 5 
minutes and the supernatant replaced with 1x PBS+0.1% BSA and incubated with 
antibodies from BD Biosciences (10uL/million cells) for CD14 and CD34 for 15 minutes 
at room temperature (Table 4). The cells were then washed with 1x PBS from Life 
Technologies with 0.1% bovine serum albumin (BSA) from Life Technologies, pelleted 
at 300rcf and resuspended in 1x PBS + 0.1% BSA along with calcein violet (1ul/1ml 
PBS) and incubated for 20 minutes. Viable cells were sorted into 384 well plates at 120 
cells per well, and the true population frequency of the three cell lines was quantified via 
the cell surface marker gating and the plates were frozen at -20°C.  
Multiplex PCR   
First-round outer product was generated with 1x Platinum Taq and Platinum Taq 
PCR Buffer from Invitrogen, 2.5mM MgCl2, 400nM dNTP, and 50nM of each individual 
primer. PCR conditions were 95°C for 5 minutes followed by 30 cycles of 95°C for 20s, 
57°C for 45s and 72°C for 45s followed by a termination extension of 72°C for 5 
minutes. The presence of bands was initially confirmed with ethidium bromide (EtBr) on 
a 2% agarose gel at 45 cycles before lowering the number of cycles to 30 for the two-step 
nested procedure.  
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Nested PCR 
Inner round product was created with either biotinylated forward or reverse 
primers and a non-labeled complement. 2μL of first round product was added to each 
separated inner target reaction which consisted of 1x Platinum Taq and Platinum Taq 
PCR buffer, 1.5mM MgCl2, 200nm dNTP, and 200nM of the labeled primer pair. Inner 
product  PCR conditions were 95°C for 5 minutes followed by 35 cycles of 95°C at 15s, 
57°C for 30s and 72°C for 30s. The presence of bands was again confirmed on a 2% 
agarose gel and EtBr.  
Pyrosequencing 
Product of the nested PCR reaction was submitted to in-house pyrosequencing on 
a PyroMark Q96 instrument from Qiagen present at the Fred Hutchinson Cancer 
Research Center along with 10mM aliquots of the pyrosequencing primers. 
Pyrosequencing results were analyzed using a tailored R-Script program related to the 
Cell Sampling program. 
Whole-Cell Input 
Whole cell PCR was tested prior to the pooling of the cell lines to ensure 
effectiveness of the primers in a whole cell setting. MOLM14-L1 cell lines were grown 
in FBS and diluted with PBS to form stocks of 500, 50, and 5 cells per microliter. 2μL of 
the cell stocks were then added to 13μL molecular biology grade H2O (Mediatech), 
frozen at -80° C,  heated to 95°C for 5 min, and then put on ice immediately prior to 
PCR.  10μL of Master Mix (1x PCR buffer, 2.5mM MgCl2, 400nM dNTP, 0.05μM 
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multiplex primers, and 1x Platinum Taq) was added to the lysate. First-step multiplex 
PCR was done at 95°C for 5 min, 40 cycles of 95°C for 30s, 57°C for 45s, 72°C for 45s 
and a final extension at 72°C for 5min. The product was run on a 2% agarose gel with 
EtBr. 
Sanger Sequencing 
Samples of the inner targets were prepared for Sanger sequencing with PCR 
amplification from each cell line and purified using the ExoSAP protocol by 
ThermoFisher Scientific. The product was submitted to be sequenced in-house on an 
Applied Biosystems (ABI) 3730xl DNA Analyzer at the Fred Hutchinson Cancer 
Research Center. The results were viewed using FinchTV by Geospiza. 
Fragment Analysis  
To analyze the relative level of FLT3-ITD in each replication a sample of each 
replication was analyzed with DNA fragment analysis by capillary electrophoresis. 
Samples from individual replications were input into a PCR reaction (1x Platinum Taq 
and Platinum Taq Master mix, 50mM MgCl2, and 10mM dNTP) with 10μM FLT3 
reverse primer and 10μM FLT3 forward primer labeled with a FAM fluorescent tag 
which absorbs at 492 nm and emits at 517 nm. The PCR product was diluted 1:10,000 
and submitted to in-house genomics analysis via ABI 3730xl DNA Analyzers. 
Cell Line DNA Titrations 
Titrations of cell line DNA were produced by diluting that DNA (KG1α, 
MOLM14, or OCI-AML3) in a differing cell line DNA (KG1α, MOLM14, or OCI-
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AML3) which did not contain a specific mutation while maintaining a constant DNA 
input of 40ng.  
Data Analysis 
The program Cell Sampling was created in R-script for this project and utilizes 
the user-defined cell line parameters along with the number of replication of cell draws 
designated to simulate both bulk allele frequency and allele frequency correlation 
coefficients, identifying mutations which track together (Appendix 4). The program first 
creates a bulk cell count that simulates a whole tumor, randomly selects a set number of 
cells, categorizes the cell types, uses the known VAF for each cell line to calculate the 
total number of each mutant allele, and finally divides it by the total number of alleles 
(Figure 8). The VAF of every target mutation is then plotted against every other 
mutation for each individual replication. The correlation between each two mutations 
across replications is analyzed with the Pearson Pairwise method to determine the level 
of association between mutant alleles. The cell sampling program also repeats the 
experiment for a range of cell inputs to identify the ideal cell count that minimizes the 
mean correlation between unlinked loci in order to maximize observable correlations 
between linked loci. Finally Cell Sampling also sums all replicates’ VAFs to determine 
the bulk VAF for comparison (Appendices 5 and 6). 
 Due to the conflicting considerations of the restricted capacity of the PyroMark 
pyrosequencing instrument and the objective of maximizing correlation trends a median 
of twenty replicates were performed. Cellular populations were approximately 33.3% of 
each cell line (34.3% KG1α, 38.4% MOLM14-L1 and 27.3% OCI-AML3, reflecting true 
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proportions as counted by flow cytometry). A total population of 3 million cells was used 
and the VAFs were set equivalent to values found with Illumia’s TruSight (Table 4).  
Figure 8. Diagram of program function-Cell Sampling. n cells are drawn from a 
simulated tumor and counted. A VAF for each target is determined from the number of 
each cell line for that sample. Replicate samples are pulled from the bulk and VAFs are 
determined for each sample. Cell Sampling then plots the allele frequencies against each 
other for every replicate and calculates the correlation between every pair. 
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RESULTS 
Establishment of VAF in Cell Lines 
Mutant allele frequencies of each cell line (or shared in two) were previously 
established through next generation sequencing via Illumina’s TruSight Myeloid 
Sequencing (Table 1) (“TruSight Myeloid Sequencing Panel,” 2015). The sequencing 
revealed that the KG1α line contains the mutation TET2-V218M (GTG>ATG) at 50% 
VAF, EZH2-G628 (GGC>AGC) at 100% VAF. MOLM-14-L1 cells contain TET2-
V218M (GTG>ATG) at 50% VAF, the FLT3-D835 mutation at 50%VAF as well as a 
21bp long FLT3-ITD. Finally, OCI-AML3 contains the DNMT3α-R882 mutation at 50% 
VAF, the NRAS-Q61 mutation (CAA>CTA) at 100% VAF and STAG2-L526F 
(CTT>TTT) at 25% VAF.  
Table 1. Variant allele frequencies of seven targets present in our three cell lines and 
the antibody markers used for identification. VAFs were found through next gen 
sequencing (Illumina). 
Cell Line DNMT3α EZH2 
FLT3-
D835 
FLT3-
ITD 
NRAS-Q61 STAG2 TET2 Marker Tags 
KG1α 0% 100% 0% 0% 0% 0% 50% CD34+/CD14- 
MOLM14 0% 0% 50% 50% 0% 0% 50% CD34-/CD14- 
OCI-AML3 50% 0% 0% 0% 100% 25% 0% CD34-/CD14+ 
 
Optimization of Multiplex PCR 
We first designed and tested assays which would selectively amplify target genetic 
products and exhibit no unintended products. Multiplex primers designed with 
PrimerBLAST were then analyzed in silico for their specificity in a multiplex setting 
using MFEprimer-2.0; no extraneous amplicons were observed and bands were seen to be 
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discrete enough to proceed to testing (Figure 9). The primers were validated in 
singleplex PCR to generate a single, specific band (Figure 10), and the multiplex 
displayed all seven target amplicon bands for both DNA input and whole cell input 
(Figure 11 and Figure 12).   
Figure 9. In silico PCR of multiplex PCR reaction, generated with MFE-Primer 2.0.  
Primer sequences from Appendix 1 were input into the internet-based application with 
PCR conditions identical to the in vitro multiplex reaction. 
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Figure 10. Nested product from second reaction produces anticipated bands.  All 
primer sets were sufficiently specific, except for the DNMT3α primer pair, which 
exhibited large amounts non-specific amplification along with the expected.    
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Figure 11. Multiplex of all three cell lines each produce seven target amplicons in 
vitro, matching in silico prediction.  MOLM14 has more ITD duplications than KG1a 
or OCI-AML3 which increases its product size. NRAS-Q61 displays an evident but faint 
band. 
 
Figure 12. Whole cell input to multiplex PCR yields amplicons identical to DNA 
input.   
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Validation of Nested Primers and Targets 
We next confirmed that the inner/nested primer pairs amplified the correctly sized 
product for both DNA-only and first-round reaction input for all targets in all three cell 
lines (Figure 13). Nested reactions with first-round input did yield a product that 
contained slightly more undesired amplicons, namely DNMT3α which showed distinct 
signs of cross amplification between unused first-round primers and second-round inner 
primers, but this was expected with nested reactions and minimized by decreasing the 
first-round cycle number and diluting the product transferred from first to second rounds. 
 
Figure 13. Non-biotinylated pyrosequencing primers produce anticipated bands 
with whole DNA input. 
 
Product from the direct DNA nested primer validation was submitted for in-house 
pyrosequencing and displayed anticipated cell line specific allele frequencies with the 
exception of EZH2 and STAG2 which displayed no mutations at all. To verify the 
mutational status of all seven genes in the cell lines the targets were sent in for Sanger 
sequencing (Figure 14). All anticipated mutations were present in expected cell lines but 
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again with the exception of EZH2 and STAG2, which were subsequently dropped from 
the multiplex and continuing experiments. 
Figure 14. Sequences of target codons for the three model cell lines found through 
Sanger sequencing.  The outlined nucleotide in each sequence represents individual 
target mutations. Bolded boxes represent mutant alleles. All possible mutations in each 
allele are not indicated, just mutations present through previous NGS. 
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Cell Sampling 
R studio program Cell Sampling returned an optimum cell draw number of about 
120 cells (Figure 15). A mean correlation between VAFs of unlinked loci over 20 reps 
was -0.36 when 120 cells were then drawn randomly from the bulk in silico, the allele 
frequencies for each allele in each cell line were set, and the VAF for each locus was 
determined for each replicate (Figure 16, Appendix 4).  
Figure 15. Determination of the optimum cell draw number via in silico cell draws.  
Mean correlation between unlinked loci was calculated with incremental numbers of cell 
drawn from the bulk to determine the cell number with the lowest correlation --and 
conversely the highest correlation between linked loci--.  
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Figure 16. VAFs plotted in silico against each other for every replication with a 
calculated correlation.  “Perfectly” linked or unlinked loci have a theoretical correlation 
of ±1 while partially linked or unlinked loci will have a partial correlation of less than |1|. 
The VAFs were determined from sampling a simulated cell population of three million 
cells with approximately one million cells from each of the three cell lines. 
 
Fragment Analysis 
A VAF for FLT3-ITD was determined by dividing the relative fluorescent 
intensity of the FLT3 peak with the ITD mutation (present at 351bp) by the intensity of 
the total FLT3 peaks (peaks at 330 bp and 351 bp) (Figure 17) (Table S4). 
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Figure 17. Example of VAF determination for FLT3-ITD.The FLT3-ITD mutation 
incorporates a seven times codon duplication, lengthening the allele by 21 base pairs, or 
from 330 bp to 351bp.  
 
Pyrosequencing 
To verify that the pyrosequencing assays are quantitative, mixtures of DNA from 
cell lines were sequenced for specific mutations. DNMT3α and NRAS-Q61 were verified 
by decreasing OCI-AML3 and increasing MOLM14-L1, FLT3-D835 was tested through 
increasing MOLM14 while decreasing KG1α and TET2 was verified through increasing 
KG1α while decreasing OCI-AML3 (Figure 18). 
 
 
 31 
 
 Figure 18. Quantifiable nature of pyrosequencing. Increasing the proportion of input 
DNA which contains designated mutations correspondingly increases the detected 
variable allele frequency. NRAS-Q61, a homologous mutation, approaches a 100% VAF 
while DNMT3α, FLT3-D835, and TET2 are heterozygous and approach 50% VAF. A 
constant DNA input of 40ng into each 2
nd
 round (inner) reaction was used with titrations 
of increasing cell line DNA (OCI-AML3 for DNMT3α and NRAS-Q61, MOLM14 for 
FLT3-D835 and KG1α for TET2 all of which were diluted with differing cell line DNA 
which did not contain the mutation.  
 
The simulated tumor population generated through cell line mixing was analyzed 
for the target allele frequencies. The twenty replications of the cell line pool were 
partitioned through flow sorting and the cell line proportions were determined to be 
34.2% KG1α, 38.4% MOLM14-L1, and 27.3% OCI-AML3, the percentages were used to 
update the program Cell Sampling for more accurate predictions in silico. Five of 
replications failed pyrosequencing due to signal errors but the remaining 15 passed 
(Figure 19 and Appendix 7). The aggregate allele frequencies in the pooled cell lines - 
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similar to what would be seen in a bulk sample- can be estimated in silico based on the 
established VAFs and the proportions of the cellular populations.  
Figure 19. FLT3-D835 Pyrographs of replicates 1-4 out of 20 total.  VAFs determined 
through pyrosequencing, in these examples guanine addition to the pyrosequencing 
primer denotes wild type alleles while thymine additions implies mutant alleles. The 
percentage denoted at Position 1 represents the VAF for a specific allele in a sample. 
Replicate 4 failed due to signal error. 
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Correlation Analysis 
The VAFs determined from the successful pyrosequencing were then plotted 
against each other for each replicate and the correlations between each allele were 
determined using the Pearson-Pairwise method (Figure 20). 
Figure 20. Experimentally derived mutant allele frequencies across replications.  
Correlation values between replicates were determined through the Pearson-Pairwise 
method.  
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DISCUSSION 
 
While clonal diversity appears to be a prospective measurement of the 
malignancy of cancer, its evaluation presents difficulties in clinical implementation. Time 
and effort factors support high-throughput bulk sequencing but, while the assumptions 
are often superficially accurate and useful for a cursory evaluation, it ultimately mis-
defines clonal diversity and the sub-clonal populations (Hughes et al., 2014). The goal of 
our project is to primarily illustrate the possible information that is overlooked by bulk 
NGS and secondarily to propose, through in silico and in vitro proof-of-concept models, 
a possible method of assessing the clonal diversity. 
Next Generation Sequencing Anomalies  
The seven mutant allele targets chosen for this low-throughput clonality assay 
were found with Illumina’s TruSight Myeloid Sequencing Panel performed on each 
individual cell line. Subsequent Sanger and pyrosequencing revealed, however, that the 
mutations EZH2 and STAG2 were not present in the leukemia cell lines we used and thus 
were not appropriate markers for tracking cellular populations. The allele targets with 
their sequencing and amplifications primers were dropped from further experiments. 
Sequencing panels are useful for genetic analysis of a broad range of targets but Sanger 
sequencing offers a much more robust and target specific method of specific codon 
evaluation. With only five targets remaining in the low-throughput clonality assay, 
specificity, and the ability to pick out clonal populations, was decreased. This outcome 
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demonstrates that next generation sequencing data, even when it meets quality control 
criteria, may need to be viewed as preliminary and separately verified. 
Bulk Variant Allele Frequency Evaluation 
 The “bulk” approach is to use the total allele frequencies of a sample to make 
statements on the clonal populations. However, these clonal assertions based on NGS 
data are one dimensional guesses and offer little opportunity for extrapolation. Seemingly 
identical frequencies which may imply common allele mutations within a clone may in 
fact just be happenstance. This effect can be seen in the approximated bulk VAFs, 
connections between various alleles can be guessed at but have no supporting evidence 
(Appendix 6). Trying to establish clonal populations through in vivo bulk NGS would 
complicate the task by likely adding more clones and incorporating experimental error. 
Multisampling adds another dimension to allele frequency analysis permitting that more 
reliable assertions of clonal structure be made. 
Computational Simulation 
To test the potential efficacy of multisampling we wrote an R-script program 
named Cell Sampling, which was successful as a preliminary proof-of-concept. Although 
this approach requires previously establishing and verifying the VAFs of the mutant 
alleles in the separate cell lines it proved an excellent starting model for predicting 
correlations and clones. By pulling replicated low-throughput count draws from a 
simulated bulk sample the program was able to correctly determine the correlations 
between every mutant allele that were known to occur in the same cell line. With simple 
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alterations the program could be used to predict correlations between different allele 
targets and cell lines. In time, the program could develop into a powerful model for future 
clinical low-throughput clonality assays where it could be used to determine which alleles 
to target in a patient to get the most definitive in vivo clonality evaluation. The program 
can also be “reverse engineered” into a new, separate program which takes correlations 
between target alleles and predicts the present clones. Much more work would be 
required to reach these stages but the Cell Sampling program, and in silico modeling with 
R-script, was an extremely useful and cost saving means to model an experiment and test 
the hypothesis. 
Data Management 
One of the goals of this project was to see what kind reliability was attainable 
from the pyrosequencing results and how the in vitro results compare to the in silico. 
What level of correlation is a true association and what is random background noise? By 
establishing the mixture of clonal populations ourselves, with the known mutational allele 
frequencies established though sequencing panels and Sanger sequencing, it is possible to 
know what correspondences are expected from the pyrosequencing results and interpret 
the correlations accordingly. With that knowledge we were able to determine that in our 
data set correlation values which were between 0.33 and -0.33 were the product of 
random association and equivalent with no allele linking. Conversely, mutant alleles with 
correlation values greater than 0.34 or less than -0.34 appear to be representative of either 
positive or negative correlation respectively. For this preliminary experiment it was 
necessary to know the actual clonal populations and set the correlation limits to prevent 
 37 
false positives or false negative correlations. With more work increased specificity 
leading to limits closer to zero and correlation coefficients of linked genes closer to 1 or -
1 might be attained, allowing for more accurate clonal discrimination and eventually the 
ability to determine the clonal structure without prior knowledge of its composition. 
Several replications were removed from final correlation analysis. Replicates 4, 5, 
12, 13 and 20 were reported to have as saturated signal errors by the pyrosequencing 
instrument for one or more of the targets and so the entire replicate was removed from 
correlation analysis and clonal extrapolation. Additionally, the presence of univariate 
outliers between the inter-replicate VAFs were identified through interquartile range 
(IQR) statistical analysis (Rousseeuw & Hubert, 2011). Replicates which contained a 
VAF value below or above the first and third quartile respectively by more than 1.5 times 
the IQR for that VAF were also removed from correlation analysis (replications 1 and 
14). The reason for the presence of the outliers is suspected, but not proven, to be due to 
exponential error propagation originating from the nested PCR step (Appendix 7). While 
the proportional amount of data points removed from this study, seven out of twenty in 
total, is unfortunate, the reasons for the removals are explicit and seen to be valid. 
Increased expertise and practice with the low-throughput clonality assay should lower the 
amount of removals in the future. 
Low-Throughput Clonality Assay  
The correlation between any two alleles in a population may be in one of three 
states depending on common mutations between the clones: 1) Uncorrelated, where 
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alleles are not wholly shared between clones, or for which experimental variation 
significantly impacts correlations determined, 2) Positive correlation, where alleles are 
wholly shared between clones, 3) Negative correlation, where mutations are mutually 
exclusive i.e. if a clone does not contain mutation A then it must contain mutation B.  
When limiting the scope of the evaluation of the pyrosequencing results to solely 
DNMT3α associations it can been seen that the DNMT3α mutation has a positive 
correlation to the NRAS-Q61 mutation that is also present in OCI-AML3 cells, a negative 
correlation to the TET2 mutation which is not present in OCI-AML3 but present KG1α 
and MOLM-14, and no correlation to the FLT3-D835 or FLT3-ITD mutations (Figure 
21). Thus, while the DNMT3a mutation and the FLT3-D835 mutation occur at 
approximately the same VAF in the bulk, via cell sampling, we can determine that they 
are not actually present in the same clone. By identifying which variants do or do not 
correlate with each other we can refine our proposed clonal structure identified via the 
bulk data.   
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Figure 21. Correlations between DNMT3α and other target mutant alleles.  Three 
possible correlation states are possible between any two alleles; uncorrelated, positively 
correlated or negatively correlated.  
 
 
By expanding the scope of focus to include all five targets and their correlations 
to each other the clonal model can be further refined (Figure 20). The NRAS-Q61 
mutation also negatively correlates with the TET2 mutation, supporting the previous 
assertion that the clones with the NRAS-Q61 and DNMT3α mutations form an opposing 
group of clones from those with the TET2 mutation. The FLT3 mutations are positively 
correlated, indicating that they are in the same clone, but are uncorrelated with anything 
else, suggesting that they comprise a subpopulation within either of groupings. In all, the 
 40 
in vitro low-throughput clonality assay was able to correctly determine the minimum 
number of clones, the presence of the two groupings of clones and the positive 
correlations between uniquely shared mutations (DNMT3α with NRAS-Q61 and FLT3-
ITD with FLT3-D835). 
Despite what the low-throughput clonality assay was able to determine, several 
clonal characteristics known to be true were not seen in the results. The FLT3 mutations 
are known to inhabit a sub clonal population with the TET2 mutation but a positive 
correlation between the two was not observed (Figure 22). In fact, the FLT3 mutations--
which were not whole shared with any other mutation besides each other--were not seen 
to correlate positively or negatively with any other mutant alleles and were responsible 
for all of the uncertainty in the assay. This implies that a mutation that is shared across 
two clones does not appear to correlate with a mutation that is in one of said clones in a 
way that is currently detectable with this system. This may occur because as cells are 
randomly sorted into replicates the VAF of the unshared mutation may fluctuate wildly as 
individual cell proportions change but the VAF of the shared mutation stays relatively 
constant as the overall cell proportions are constant. Increases in sensitivity through 
expertise and practice should lower the random correlations (i.e. noise) and permit 
detection of partially linked mutations. However, this factor represents a potential flaw in 
the multi-sampling model and requires further testing and modeling. Also unseen in this 
assay is the homozygous nature of the NRAS-Q61 mutation in the OCI-AML3 cells. By 
examining the mean VAF from all replicates it can be seen that the average VAF of 
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NRAS-Q61 is twice that of DNMT3α and so may be estimated to be homozygous but 
also may simply be allele bias. 
Figure 22. Predicted vs. experimental results. Lower Left: red lines indicate the 
experimentally derived correlations between VAFs and green lines indicate in silico 
correlation predictions. Upper Right: whether the correlations between the two mutant 
alleles that were predicted in silico was observed in vitro.  
 
The low-throughput/multi-sampling clonality assay offers a more accurate picture 
on the clonal populations and diversity present in a sample than simple bulk analysis. It 
verified in part, the in silico modeling by Cell Sampling and supported the multisampling 
practice. More time invested in the assay to increase proficiency should increase 
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specificity and more results may make any shortcomings or possible improvements of the 
model more evident. This data could then be implemented back into Cell Sampling to 
improve its prediction accuracy.  
The low throughput clonality assay does entail several drawbacks. High-
throughput bulk analysis may overlook rare sub-clones due to high allele frequency 
background noise, but low-throughput may miss rare sub-clones simply because fewer 
cells are targeted and the chosen target mutations must necessarily be common to many 
diverging cell lines. The low-throughput clonality assay protocol entails that for each 
unique set series of allele targets are appraised the multiplex primer mixture must be re-
designed. The nested PCR portion of experimental method is sensitive to contamination 
and can result in exponential error propagation. Finally the assay has difficulty in 
determining the correlations between alleles where one allele is shared across multiple 
clones. Overall the assay did an excellent job of demonstrating the limitations of NGS 
bulk samples, supporting the in silico model and offer a potential alternative to bulk 
sampling. 
With improvements the assay may also offer some clinical applicability as it has 
several benefits over bulk sequencing: 1) A majority of the equipment used, with the 
possible exception of the PyroMark Q96 instrument, is commonly found in research labs 
2) Non-cancerous HSPC or other cell populations in the samples will not skew the 
correlations between two mutant alleles in the way that is found in bulk sequencing. 3) 
The assay makes no assumptions of zygosity in its population determination and is thus 
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less likely to overestimate a clone’s population size.  4) Extremely small samples may be 
used –our experiment only used ~ 2400 cells in total--. The low-throughput clonality 
assay, with more work, may be a clinically viable option for assessing clonal diversity 
and populations. 
Future Work 
The program Cell Sampling and the low-throughput clonality assay both function 
well as proof-of-concepts but also leave room for development. Optimization of the PCR 
reaction’s conditions (i.e. salt concentrations, stage times, or nucleotide concentrations) 
and the multiplex primers may increase sensitivity and should be verified. Testing more 
variations in cellular proportions and sample sizes would increase the number of data 
points for analysis, allowing for more accurate determination of correlations between 
linked and unlinked mutant alleles, theoretically approaching the values determined in 
Cell Sampling. Increasing the number of targets would also increase the number of data 
points and allow the differentiation of similar clones, with more targets increasing 
specificity. By incorporating distorting factors such as primer biases and potential 
amplicon interactions into the Cell Sampling computer model the program could more 
accurately predict pyrosequencing results, speeding development through in silico 
experimentation. Finally, a reverse direction computational program which distinguishes 
unique and unknown clones from a multi-sample’s pyrosequencing results would be a 
large step toward clinical applicability for the multiplex/nested/pyrosequencing protocol. 
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APPENDIX 
Appendix 1. Multiplex primers for the first-round product found through 
PrimerBLAST and verified in silico with MFEPrimer 2.0. 
Gene/Primer-Name 
Product 
(bp) 
Direction Sequence (5’ to 3’) 
DNMT3α-SP-F/R 237bp 
F GTGTGGTTAGACGGCTTCCGG 
R CTCAGTTTGCCCCCATGTCCCTT 
EZH2-SP-F/R 571bp 
F CTCGAGGAAATCAAGGGCTGAAGAT 
R CATGCAGAAGTCCAGGCTGAAAAG 
FLT3-ITD-SP-F/R 453bp 
F CTTTCCTCTATCTGCAGAACTGCCT 
R GCATGGGTGGGAAACTGTGCCT 
FLT3-D835-SP-F/R 522bp 
F CTCACGGCACAGCCCAGTAAAGA 
R TTGCACTCAAAGGCCCCTAACTGAT 
NRAS–Q61-SP-F/R 342bp 
F GGCAATAGCATTGCATTCCCTGTGGT 
R CCTAGTGTGGTAACCTCATTTCCCCATA 
STAG2-SP-F/R 400bp 
F GTGGCATATAGGGAGAAGAAATAAGCTAA 
R CATGAAGGCAGGGACTGTCAATCA 
TET2-SP-F/R 313bp 
F CACATAACTGCAGTGGGCCTGAAA 
R CCTGAGGTATGCGATGGGTGAGT 
 
Appendix 2. Inner primers for nested reaction, found through Qiagen Pyromark 
software. One of each paired primers were biotin tagged for pyrosequencing except for 
FLT3-ITD which was has a fluorescing FAM marker for fragment analysis. 
Gene/Primer Name 
Product 
(bp) 
Direction Sequence/Biotin (5’ to 3’) 
 DNMT3α-Pyro-F/R 65bp 
F  CCCAGTCCACTATACTGACGTCTC-Biotin 
R  ACCGGCCCAGCAGTCTCT 
 EZH2-Pyro-F/R 69bp 
F  CATCTATTGCTGGCACCATC-Biotin 
R  CATTTTTCTGCACAGGATCTTTG 
 FLT3-D835-Pyro-F/R 96bp 
F  AGGAACGTGCTTGTCACCC 
R  GCCCCTGACAACATAGTTGGA-Biotin 
 NRAS-Q61-Pyro-F/R 85bp 
F  CCTGTTTGTTGGACATACTGGATACAGC-Biotin 
R  AAGCCTTCGCCTGTCCTCATGTA 
 STAG2-Pyro-F/R 82bp 
F  ACTAACAGATAGGCAAGAGAGT-Biotin 
R  CACGGGAGGATGACATTC 
 TET2-Pyro-F/R 120bp 
F  GCTAATGCCTAATGGTGCTACA 
R  GTTTTCTGCACCGCAATGGAA-Biotin 
 FLT3-ITD 330bp 
F  AGCAATTTAGGTATGAAAGCCAGC-FAM 
R  CTTTCAGCATTTTGACGGCAACC 
 45 
Appendix 3. Sequencing primers for pyrosequencing, found with Qiagen Pyromark 
software.  
 Gene/Name Direction Sequence (5’ to 3’) 
DNMT3α-seq R AGTCTCTGCCTCGCC 
EZH2-seq R TGATAAAAATCCCCCA 
FLT3-D835-seq F GATATGTGACTTTGGATTG 
NRAS-Q61-seq R CATGGCACTGTACTCTTCT 
STAG2-seq R GCTTGTCTAATGGTACAAA 
TET2-seq F GCTACAGTTTCTGCCTCT 
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Appendix 4. Cell sampling program R-script program written to simulate an AML 
patient and calculate the correlations between mutant alleles with the goal of evaluating 
the clonal structure.  
 
 
Weston Christensen 
October 20, 2015 
Initialization parameters 
#install.packages("knitr", "ggplot2", "polynom") 
library('knitr') 
library('ggplot2') 
library('polynom') 
 
#cells<-120          #Cells drawn per rep (NULL when cell# is determined by correlation) 
reps<-20             #Number of draws from bulk 
totalcells<-300000   #Total cell count in bulk 
KG1a<-0.343              
MOLM14<-0.384        #Cell percentages 
OCIAML3<-0.273 
set.seed(0) 
 
#Cell-line Matrix Generator 
celllines<-matrix(c(0,0,0,0,.5,0,.5,.5,0,.5,.5,0,0,1,0), ncol =5, byrow = T) 
colnames(celllines)<-c("DNMT3a","FLT3-D835","FLT3-ITD", "NRAS-Q61", "TET2") 
rownames(celllines)<-c("KG1a","MOLM14", "OCI-AML3") 
kable(celllines, caption = "Variable Allele Frequencies for 3 AML cell lines") 
 
Variable Allele Frequencies for 3 AML cell lines (fraction). 
Cell Lines DNMT3α FLT3-D835 FLT3-ITD NRAS-Q61 TET2 
KG1a 0.00 0.00 0.00 0.00 0.50 
MOLM14 0.00 0.50 0.50 0.00 0.50 
OCI-AML3 0.50 0.00 0.00 1.00 0.00 
 
Sampling Function 
#initiates Sampling function 
Sampling<-function(cellsf, repsf, KG1af, MOLM14f, OCIAML3f, celllinesf, totalcellsf) 
  { 
   
#Creates and fills VAFtable (VAFt) with titles 
VAFt<-matrix(data=NA, nrow=repsf, ncol=5) 
colnames(VAFt)<-c("DNMT3a","FLT3-D835","FLT3-ITD", "NRAS-Q61", "TET2")  
rownames(VAFt)<-c(paste("Rep",1:repsf))         
 
#creates vector "bulk" and fills it with the total cell number(Sum of percentage*total) 
bulk<-c(rep("KG1a", (KG1af*totalcellsf)), rep("MOLM14",(MOLM14f*totalcellsf)), rep("OCI-AML3", (
OCIAML3f*totalcellsf))) 
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#builds table "samples" and fills it with cell# of 
rownames(samples)<-c(paste("Cell -",1:cellsf)) 
 
#For loop that fills VAFt from each rep 
i<-0 
for (i in 1:repsf)  
  { 
   
#Counts cell numbers in each rep and fills it into vector count 
count<-c((sum(samples[,i] == "KG1a")),(sum(samples[,i] == "MOLM14")), (sum(samples[,i] == "OCI-A
ML3")))     
 
#multiplies count of each cell type times 2 alleles, multiplied by VAF and sums, then divides by total allele
s 
DNMT3a<-(sum(2*count[1]*celllinesf[1,1],2*count[2]*celllinesf[2,1], 2*count[3]*celllinesf[3,1])/(2*cells
f)) 
D835<-(sum(2*count[1]*celllinesf[1,2],2*count[2]*celllinesf[2,2],  2*count[3]*celllines[3,2])/(2*cellsf)) 
ITD<-(sum(2*count[1]*celllinesf[1,3],2*count[2]*celllinesf[2,3], 2*count[3]*celllinesf[3,3])/(2*cellsf)) 
NRAS<-(sum(2*count[1]*celllinesf[1,4],2*count[2]*celllinesf[2,4], 2*count[3]*celllinesf[3,4])/(2*cellsf)) 
TET2<-(sum(2*count[1]*celllinesf[1,5],2*count[2]*celllinesf[2,5], 2*count[3]*celllinesf[3,5])/(2*cellsf)) 
 
#fills VAF table with vectored VAF for each rep 
VAFt[i,]<-c(DNMT3a,D835,ITD,NRAS,TET2)    
} 
 
#data frames VAFt into dat 
dat.VAF<-data.frame(VAFt) 
 
return(dat.VAF) 
} 
 
Calculates mean correlation for un-linked loci for based on cell number 
#for loop establishing parameters, min/max cell number 
min<-75 
max<-150 
b<-min 
 
#Creates Correlation table "cor.table"  
cor.table<-matrix(data=NA, ncol=2, nrow=max) 
 
#for loop incrementing cells or reps 
for (b in  min:max) 
  { 
   
#Number of cells drawn from bulk per rep, changing to reps will produce similar results but for reps instead 
cells <- b 
 
#calls sampling function 
dat.VAF<-Sampling(cellsf=cells, repsf=reps, KG1af=KG1a, MOLM14f=MOLM14, OCIAML3f=OCIAM
L3, celllinesf=celllines, totalcellsf=totalcells) 
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#averages the correlations for the un-linked locci 
cor.vect<-mean(c( 
  cor(dat.VAF$FLT3.D835, dat.VAF$DNMT3a), 
  cor(dat.VAF$FLT3.D835, dat.VAF$NRAS.Q61), 
  cor(dat.VAF$FLT3.D835, dat.VAF$TET2), 
  cor(dat.VAF$FLT3.ITD, dat.VAF$DNMT3a), 
  cor(dat.VAF$FLT3.ITD, dat.VAF$NRAS.Q61), 
  cor(dat.VAF$FLT3.ITD, dat.VAF$TET2), 
  cor(dat.VAF$TET2, dat.VAF$NRAS.Q61), 
  cor(dat.VAF$TET2, dat.VAF$DNMT3a) 
  )) 
   
#Fills CoVar table with mean CoVar for each cell count 
cor.table[b,]<-c(b,cor.vect) 
} 
 
#dataframe fixes cor.table and names 
dat.cor<-na.omit(data.frame(cor.table)) 
colnames(dat.cor)<-c("Cell Number","Mean Correlation") 
 
#plots cor.tablr with CI 
g<-ggplot(data=dat.cor, aes(`Cell Number`,`Mean Correlation`))+ geom_point()+stat_smooth(method = "l
m", formula = y ~ poly(x, 2), size = 1)+ylim(-.55,-.15)+scale_x_continuous(breaks=c(75,100,125,150), exp
and = c(0.01, 0.01)) 
 
#Extracts Coefficients and solves for min Covariance (as long as there are zeros) 
Coeff<-coef(lm(formula = dat.cor$'Mean Correlation' ~ dat.cor$'Cell Number' + I(dat.cor$'Cell Number'^2
))) 
p<-polynomial(Coeff) 
p<-solve(p) 
OptCellDraw<-mean(p) 
print(c("Optimum Cell Draw Count =",OptCellDraw)) 
## [1] "Optimum Cell Draw Count =" "118.043096549912" 
g<-g+annotate("text", x =120, y = -.175, label = "Optimum Cell Draw =") 
g<-g+annotate("text", x=135.2, y= -.175, label = round(OptCellDraw,0)) 
g 
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Determination of the optimum cell draw number via in silico cell draws.  
 
Creates VAF figure Using Sampling Function and cell number from previous function 
#cells<-ceiling(OptCellDraw) 
cells<-OptCellDraw 
 
#calls Sampling function to fill dat.VAF 
dat.VAF<-Sampling(cellsf=cells, repsf=reps, KG1af=KG1a, MOLM14f=MOLM14, OCIAML3f=OCIAM
L3, celllinesf=celllines, totalcellsf=totalcells) 
 
#Table of VAF means 
mean.table<-matrix(round(c(mean(dat.VAF$DNMT3a),mean(dat.VAF$FLT3.D835),mean(dat.VAF$FLT3
.ITD),mean(dat.VAF$NRAS.Q61),mean(dat.VAF$TET2)),3),byrow=T) 
  rownames(mean.table)<-c("DNMT3a","FLT3-D835","FLT3-ITD", "NRAS-Q61", "TET2") 
  colnames(mean.table)<-"Mean VAF" 
  kable(mean.table, caption="Mean Target VAFs, Representative of the Bulk data") 
 
Mean Target VAFs, Representative of the Bulk data 
Target Mean VAF 
DNMT3α 0.131 
FLT3-D835 0.198 
FLT3-ITD 0.198 
NRAS-Q61 0.263 
TET2 0.369 
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#graphs dat.VAF with best fits and correlations 
pairs(dat.VAF, diag.panel = NULL, upper.panel=NULL, lab=c("DNMT3a","FLT3-D835","FLT3-ITD","N
RAS-Q61", "TET2"), xaxs="r",  xaxp=c(.25,.75,2), xlim=c(0,1), ylim=c(0,1), yaxs="r", yaxp=c(.25,.75,2), 
gap=.25, cex.labels=1.1, panel=function(x, y, digits=2, prefix="",cex.cor,... ){        #function creates best fit
 lines for scatterplots 
    points(x,y, col='azure4')            
    abline(lm(y~x), col='red') 
     
  #Adds Pearson Correlation     
    usr <- par("usr"); on.exit(par(usr)) 
       par(usr = c(0, 1, 0, 1), font=2) 
       r  <- cor(x, y,use="pairwise", method="pearson") 
       txt <- format(c(round(r,digits), 
       0.123456789), digits=digits)[1] 
       txt <- paste(prefix, txt, sep="") 
       text(0.75, .92, txt,cex=1) 
}) 
 
#averages the correlations of the unlinked locci 
cor.vect<-mean(c( 
  cor(dat.VAF$FLT3.D835, dat.VAF$DNMT3a), 
  cor(dat.VAF$FLT3.D835, dat.VAF$NRAS.Q61), 
  cor(dat.VAF$FLT3.D835, dat.VAF$TET2), 
  cor(dat.VAF$FLT3.ITD, dat.VAF$DNMT3a), 
  cor(dat.VAF$FLT3.ITD, dat.VAF$NRAS.Q61), 
  cor(dat.VAF$FLT3.ITD, dat.VAF$TET2), 
  cor(dat.VAF$TET2, dat.VAF$NRAS.Q61), 
  cor(dat.VAF$TET2, dat.VAF$DNMT3a) 
  )) 
 
 
mtext("Mean VAF correlation",adj=.8,padj=5)  
mtext(round(cor.vect,4), adj=.8,padj=7) 
mtext("Cell Draw Number", adj=.76, padj=9) 
mtext(round(cells,0), adj=.77, padj=11) 
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VAFs plotted in silico against each other for every rep with a calculated correlation. 
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Appendix 5. VAFs determined through in silico cell sampling of the simulated bulk 
and extrapolation of VAFs. Bulk contains all three cell lines and proportions are 
reflective of the true proportions determined through flow cytometry. 
Rep DNMT3α FLT3-D835 FLT3-ITD NRAS-Q61 TET2 
Rep 1 0.12 0.23 0.23 0.24 0.38 
Rep 2 0.09 0.19 0.19 0.18 0.41 
Rep 3 0.14 0.16 0.16 0.29 0.36 
Rep 4 0.12 0.20 0.20 0.25 0.38 
Rep 5 0.13 0.17 0.17 0.25 0.37 
Rep 6 0.14 0.19 0.19 0.28 0.36 
Rep 7 0.11 0.20 0.20 0.23 0.39 
Rep 8 0.16 0.18 0.18 0.31 0.34 
Rep 9 0.17 0.16 0.16 0.33 0.33 
Rep 10 0.13 0.21 0.21 0.25 0.37 
Rep 11 0.13 0.21 0.21 0.25 0.37 
Rep 12 0.14 0.23 0.23 0.28 0.36 
Rep 13 0.13 0.19 0.19 0.25 0.37 
Rep 14 0.13 0.19 0.19 0.26 0.37 
Rep 15 0.13 0.20 0.20 0.25 0.37 
Rep 16 0.13 0.20 0.20 0.25 0.37 
Rep 17 0.11 0.23 0.23 0.21 0.39 
Rep 18 0.13 0.23 0.23 0.26 0.37 
Rep 19 0.15 0.18 0.18 0.30 0.35 
Rep 20 0.16 0.20 0.20 0.31 0.34 
Mean 0.13 0.20 0.20 0.26 0.37 
STD Dev 0.02 0.02 0.02 0.04 0.02 
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Appendix 6. Allele frequencies calculated from actual population proportions. With 
the mutated allele frequencies for each cell line determined through sequencing and the 
composition of the cell line mixture determined though flow cytometry the total allele 
frequency for each target can be determined, simulating a bulk analysis. Identical 
frequencies between FLT3-ITD and FLT3-D835 indicate being in a similar clone. 
DNMT3α frequency is half of that NRAS-Q61 indicating either that they are in the same 
clones at a different zygosity or that a subpopulation division occurred. TET2 and 
DNMT3α have a combined allele frequency of exactly 50% indicating that the whole 
population shares either or the other mutated allele. It should be noted that increasing 
targets and cell populations will dramatically complicate the picture and lineages would 
be much harder to pick apart. 
Target Allele Frequency 
DNMT3α 13.65% 
FLT3-D835 19.2% 
FLT3-ITD 19.2% 
NRAS-Q61 27.3% 
TET2 36.35% 
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Appendix 7. Pyrosequencing and fragment analysis allele VAF results in percentage 
from the low-throughput clonality analysis on cell line mixture.  Rows highlighted in 
light red were removed from correlation calculations due to either pyrosequencing failure 
or the presence of outliers which were detected using the interquartile range [1.5IQR 
below first quartile or above 3
rd
 quartile] highlighted in dark red. Mean values differ from 
the in silico simulation however, as long as the correlation between VAFs is constant the 
actual value may fluctuate.  
Replication DNMT3a FLT3-D835 FLT3-ITD NRAS-Q61 TET2 
Rep 1 27.6 17.1 24.6 89.7 26.4 
Rep 2 27.1 24.5 28.9 86.9 43.8 
Rep 3 31.1 26.9 38.0 80.2 41.5 
Rep 4 26.3 FAIL 34.0 FAIL 39.7 
Rep 5 36.6 23.7 20.2 FAIL 29.9 
Rep 6 40.2 26.3 33.3 87.9 40.2 
Rep 7 36.0 12.3 35.4 81.8 40.7 
Rep 8 39.4 17.4 35.7 92.1 29.5 
Rep 9 37.3 19.0 26.7 84.8 33.9 
Rep 10 22.7 20.6 32.3 78.5 47.0 
Rep 11 27.6 17.4 37.4 80.0 39.9 
Rep 12 30.8 14.1 30.3 FAIL 45.3 
Rep 13 25.3 FAIL 33.1 93.0 57.6 
Rep 14 38.5 19.2 36.6 65.3 43.4 
Rep 15 34.9 21.3 35.3 83.4 45.2 
Rep 16 22.5 33.1 31.0 83.5 39.3 
Rep 17 36.5 26.3 34.6 90.1 43.4 
Rep 18 32.4 29.0 39.1 91.4 35.4 
Rep 19 41.6 33.1 48.0 81.8 37.3 
Rep 20 FAIL 40.3 49.9 93.2 38.7 
Mean 33.0 23.6 32.0 84.8 39.8 
STD Dev 6.4 6.3 5.3 4.5 4.8 
1st Quartile 26.30 17.40 30.35 80.05 39.30 
3rd Quartile 37.30 25.40 35.71 87.65 45.20 
IQR 11.00 8.00 5.36 7.60 5.90 
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